| Target Price | $85.68 |
| Price | $2.86 |
| Potential |
2,895.80%
register free of charge
|
| Number of Estimates | 4 |
|
4 Analysts have issued a price target Cellectar BioSciences, Inc. 2026 .
The average Cellectar BioSciences, Inc. target price is $85.68.
This is
2,895.80%
register free of charge
$157.50
5,406.99%
register free of charge
$18.18
535.66%
register free of charge
|
|
| A rating was issued by 10 analysts: 7 Analysts recommend Cellectar BioSciences, Inc. to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Cellectar BioSciences, Inc. stock has an average upside potential 2026 of
2,895.80%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -36.52 | -12.12 |
| 65.22% | 66.81% | |
| P/E | negative |
6 Analysts have issued a Cellectar BioSciences, Inc. forecast for earnings per share. The average Cellectar BioSciences, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Cellectar BioSciences, Inc....
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Maxim Group |
Locked
➜
Locked
|
Locked | May 14 2025 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | Dec 11 2024 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | Nov 19 2024 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | Oct 11 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Maxim Group:
Locked
➜
Locked
|
May 14 2025 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Dec 11 2024 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Nov 19 2024 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Oct 11 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


